Results 91 to 100 of about 1,013 (109)

Feasibility and Efficacy of Lorlatinib in Japanese Patients With Relapsed/Refractory ALK ‐Aberrant Neuroblastoma

Lorlatinib, a third‐generation ALK inhibitor, was administered off‐label to five heavily pretreated patients with relapsed or refractory ALK ‐aberrant neuroblastoma.
Itaru Kato, Masahiro Irie, Junko Takita, Satoshi Saida, Yusuke Imanaka, Kagehiro Kouzuki, Katsutsugu Umeda, Hirohito Kubota, Yoshinori Uchihara, Ryo Akazawa, Shuro Nishio, Takashi Imazu, Ryunosuke Tojo, Kimiyoshi Sakaguchi, Yoshiyuki Takahashi   +14 more
core   +1 more source

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial

JTO Clinical and Research Reports
Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK-positive or ALK-negative advanced NSCLC, respectively. Methods: Starting doses
Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD   +18 more
doaj   +1 more source

Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression

, 2020
Background: The third-generation tyrosine kinase inhibitor (TKI) lorlatinib showed overall and intracranial anti-tumor activity in patients with ALK+ NSCLC in the ongoing phase 2 trial NCT01970865.
Soo, R. A, Thurm, H., Abbattista, A., Ou, S. I, Besse, B., Wiltshire, R. J, Bearz, A., Shaw, A., Toffalorio, F., Solomon, B., Gadgeel, Shirish M   +10 more
core   +1 more source

The dual combination therapy panobinostat-lorlatinib is effective against neuroblastomas harboring genomic TERT rearrangements and ALK mutations

THE DUAL COMBINATION THERAPY PANOBINOSTAT-LORLATINIB IS EFFECTIVE AGAINST NEUROBLASTOMAS HARBORING GENOMIC TERT REARRANGEMENTS AND ALK MUTATIONS The dual combination therapy panobinostat-lorlatinib is effective against neuroblastomas harboring genomic ...
Linke, Rasmus
core  

Clinical Management of Adverse Events Associated with Lorlatinib. [PDF]

Oncologist, 2019
Lorlatinib is a novel, highly potent, brain-penetrant, third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI), which has broad-spectrum potency against most known resistance mutations that can develop during treatment with crizotinib and second ...
Alice Shaw, Todd Bauer, Eudald Felip
exaly   +2 more sources

P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib [PDF]

International Journal of Cancer, 2018
Lorlatinib (PF-06463922) is a promising oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor currently in Phase III clinical trials for treatment of non-small-cell lung cancer (NSCLC) containing an ALK rearrangement.
Rolf W Sparidans, Alfred H Schinkel, Jos Beijnen   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

Annals of Oncology, 2021
Enriqueta Felip, Alessandra Bearz, Benjamin J Solomon   +2 more
exaly  

From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced NSCLC

Critical Reviews in Oncology/Hematology, 2023
Misako Nagasaka, Sai-Hong Ou, Alexandria Lee   +2 more
exaly  

Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies

Journal of Thoracic Oncology, 2023
Holger Thurm, Antonello Abbattista
exaly  

Recent Advances in the Management of Adverse Events Associated with Lorlatinib

OncoTargets and Therapy, 2023
Liao Dehua
exaly